The Lp(a) Test: The Once-in-a-Lifetime Genetic Lipid Check

A 44-year-old runner sits in an exam room holding a lipid panel that looks like a report card full of A’s. Her LDL is fine. Her HDL is enviable. And yet her father had a heart attack at 52, and his father before him at 55. Something in that family story isn’t showing up on the standard test — and there’s a good chance it has a name: lipoprotein(a).

Most cholesterol tests never look for it. It’s a separate particle, ordered separately, and it behaves nothing like the numbers people are used to tracking. You can’t out-jog it, out-oatmeal it, or meaningfully lower it at the pharmacy counter today. What you can do is know it.

That’s why cardiologists increasingly describe this as the rare lab test you take once, remember forever, and use to sharpen every heart decision that follows.

What is lipoprotein(a) — and why have I never heard of it?

Picture an ordinary LDL particle — the “bad cholesterol” carrier — with an extra protein tail stitched onto it. That tail, called apolipoprotein(a), is what turns LDL into lipoprotein(a), and it changes the particle’s behavior in three unwelcome ways.

First, like LDL, it ferries cholesterol into artery walls, feeding the plaque-building process. Second, the apo(a) tail structurally resembles plasminogen, a protein your body uses to dissolve blood clots; researchers believe Lp(a) may interfere with that clot-clearing machinery, tilting the balance toward clotting. Third, Lp(a) is a preferred carrier of oxidized phospholipids — inflammatory cargo that has been linked to the calcification of the aortic valve, the heart’s main exit door.

So one particle plausibly contributes to plaque, clots, and valve disease at once. That triple threat is why the National Institutes of Health and the American Heart Association now flag elevated Lp(a) as an independent risk factor for cardiovascular disease — independent meaning it raises risk even when everything else on your lipid panel looks pristine.

The particle was actually discovered back in 1963, so it isn’t new science. What’s new is the clinical attention. For decades it sat in the “interesting but untreatable” file. That file is now open, and the first step for any individual is a single blood draw.

Why is the Lp(a) test a once-in-a-lifetime check?

Your LDL cholesterol is a moving target. It drifts with diet, weight, activity, medication, even the season. Lp(a) is different: an estimated 70 to 90 percent of your level is written into a single gene, called LPA, and the level you have as a young adult is roughly the level you’ll carry at 70.

The gene works a bit like a recipe with a repeating ingredient. The apo(a) tail contains looping structures called kringles, and the number of repeats you inherit largely determines how much Lp(a) your liver produces. Fewer repeats generally means smaller particles and, counterintuitively, higher blood levels. You inherited your repeat count at conception, and no lifestyle choice rewrites it.

That genetic stability is what makes this test unusual in preventive medicine. Blood pressure needs checking yearly. Cholesterol panels repeat every few years. Lp(a), for most people, is a one-and-done measurement that quietly informs decades of decisions.

There are exceptions worth knowing. Levels can shift modestly with menopause, significant kidney disease, or an underactive thyroid, and clinicians sometimes recheck in those situations or when a first result lands in a gray zone. But for the typical adult, the European Atherosclerosis Society’s advice — measure it once in a lifetime — is the operative phrase, and it’s the reason this test earns its unusual nickname.

Why don't doctors routinely test for lipoprotein(a)?

Honest answer: for a long time, medicine followed a blunt rule — don’t measure what you can’t treat. No approved therapy specifically lowered Lp(a), so many physicians reasoned the result would only generate anxiety without changing the plan. That logic is eroding, but its momentum lingers in exam rooms.

A few other frictions kept the test off the standard menu:

• Measurement muddle. Labs have historically reported Lp(a) in two different units — mg/dL (particle mass) and nmol/L (particle count) — that don’t convert cleanly, which complicated setting universal cutoffs.
• Guideline lag. The 2018 U.S. cholesterol guideline treats high Lp(a) as a “risk-enhancing factor” to consider in selected patients, while European (2022) and Canadian (2021) guidance goes further and recommends a once-in-a-lifetime measurement for essentially all adults. U.S. practice sits somewhere between.
• Habit and awareness. The standard lipid panel is a decades-old reflex; adding a separate order requires a doctor thinking of it or a patient asking.

The tide is clearly turning. Screening rates remain low — studies suggest only a small fraction of eligible U.S. adults have ever been tested — but the combination of clearer guidelines, better assays, and promising therapies in clinical trials is moving Lp(a) from a specialist’s curiosity toward mainstream preventive care. If your doctor hasn’t mentioned it, that’s a conversation worth starting yourself.

Who should ask for a lipoprotein a test?

European and Canadian guidelines answer simply: every adult, once. If you’d rather prioritize, the case for testing is strongest when any of the following applies:

• A parent, sibling, or grandparent had a heart attack, stroke, or bypass surgery early — before 55 in men or 65 in women.
• You’ve had a cardiovascular event yourself at a young age, or events keep occurring despite well-controlled LDL cholesterol.
• You or a relative has familial hypercholesterolemia, an inherited high-LDL condition that often travels with high Lp(a).
• A family member has already tested high for Lp(a) — first-degree relatives have roughly a coin-flip chance of sharing it.
• Your calculated 10-year risk sits in an intermediate zone and your doctor needs a tiebreaker for how aggressive prevention should be.
• You have aortic valve stenosis, particularly at a younger age than typical.

Ancestry matters too, in a way worth stating plainly and without alarm: median Lp(a) levels run higher, on average, in people of African and South Asian descent than in people of European or East Asian descent. That’s a population statistic, not an individual verdict — which is precisely why measuring, rather than guessing, is the point.

One more group deserves mention: healthy people with spotless lipid panels and a nagging family story. They’re the ones for whom this single tube of blood most often changes the conversation.

How the test works: one tube of blood, no fasting required

The mechanics could hardly be simpler. A phlebotomist draws a single tube from your arm — often at the same visit as a routine lipid panel — and you don’t need to fast for the Lp(a) measurement itself. If it’s bundled with other labs, follow whatever instructions your clinician gives for those.

Two practical details save headaches later:

• It must be ordered specifically. Lp(a) is not part of a standard lipid panel. If you assume your “full cholesterol workup” covered it, you’re probably wrong. Ask the question directly: “Was lipoprotein(a) included?”
• Ask which units your lab reports. Results come as either mg/dL or nmol/L. Many experts prefer nmol/L because it counts particles rather than weighing them, and particle number tracks risk more faithfully. There’s no exact conversion between the two, since particle sizes vary from person to person — a quirk that trips up plenty of online calculators.

Timing has a few footnotes. Because levels can rise temporarily during acute illness or inflammation, it’s sensible to test when you’re in your usual state of health rather than the week after a nasty infection. And since results are stable across adulthood, there’s no “ideal age” — whenever the question of your long-term heart risk becomes real is the right time.

Results typically return within days, delivered as a single number. Interpreting that number is where the real work begins.

How to read your Lp(a) results

Risk from Lp(a) is a gradient, not a cliff — every threshold below is a convenient line drawn through a continuous slope. With that caveat, here’s how most laboratories and guidelines frame results:

Category	nmol/L (preferred)	mg/dL (approx.)	What it generally means
Desirable	Below 75	Below 30	Lp(a) is unlikely to add meaningful risk
Borderline	75–125	30–50	Gray zone; interpret alongside other risk factors
High	125 and above	50 and above	Independent risk factor; prevention plan should account for it
Very high	Roughly 430 and above	Roughly 180 and above	Lifetime risk comparable to some inherited cholesterol disorders

About 20 percent of people worldwide — an estimated 1.4 billion — land at 125 nmol/L or above. At that level, long-term risk of heart attack and stroke runs meaningfully higher than for someone with a low level, and the risk of calcific aortic valve disease climbs as well. At the very high end, some studies put lifetime cardiovascular risk in the same neighborhood as untreated familial hypercholesterolemia.

Resist the urge to read your number in isolation. A level of 130 nmol/L in a 40-year-old nonsmoker with excellent blood pressure carries different weight than the same number in someone with diabetes and a strong family history. The number is a lens, not a diagnosis — and no lab value, this one included, can tell you whether an event will actually happen.

My cholesterol is normal — can Lp(a) still be high?

Yes, and this is the scenario that makes the test valuable rather than redundant. Lp(a) levels correlate only weakly with the rest of the lipid panel. Plenty of people with textbook-perfect LDL carry strikingly high Lp(a), and their standard results offer no hint of it.

There’s even a measurement wrinkle hiding inside your LDL number. When a lab reports LDL cholesterol, the cholesterol being carried by Lp(a) particles gets lumped into that figure — the two aren’t separated. For most people the contribution is small. But in someone with very high Lp(a), a noticeable slice of their “LDL cholesterol” is actually Lp(a) cholesterol in disguise. Their true LDL may be lower than reported, while a distinct and unmeasured risk factor sits underneath, doing its own damage.

This helps explain a pattern cardiologists know well: the patient with unremarkable lipids and a coronary event in their forties, or the family where heart disease keeps arriving early despite everyone “eating right.” Studies of people who have heart attacks at young ages consistently find elevated Lp(a) overrepresented among them.

The practical takeaway is simple. A normal lipid panel answers the questions it was designed to answer — no more. If your family history and your lab results seem to be telling different stories, Lp(a) is often the missing chapter, and it takes one additional test to read it.

When should you worry about lipoprotein(a)?

“Worry” is the wrong verb — it burns energy without lowering risk. A better frame: when should Lp(a) change what you and your doctor actually do?

Concern should scale with two things: how high the number is, and what company it keeps. A level of 125 nmol/L (about 50 mg/dL) or above earns a place in your prevention plan. A level near or above 430 nmol/L (about 180 mg/dL) deserves a focused conversation, often with a lipid specialist or preventive cardiologist. And any elevated level matters more when it travels with smoking, high blood pressure, diabetes, chronic kidney disease, or a family history of early events — risk factors multiply rather than politely add.

Evidence for the stakes is solid and worth stating without drama. Large genetic and population studies link high Lp(a) to roughly a doubling of heart attack risk at the higher ranges, along with increased risk of ischemic stroke and a two- to three-fold higher likelihood of developing calcific aortic stenosis over a lifetime.

But hold those numbers next to this one: most people with elevated Lp(a) never have a heart attack. Doubling a small absolute risk still yields a small absolute risk, especially in someone who doesn’t smoke, keeps blood pressure in range, and stays active. The rational response to a high result isn’t fear. It’s precision — treating every risk factor you can control with more seriousness, because one you can’t control is along for the ride.

Can diet, exercise, or supplements lower Lp(a)?

Here’s the honest answer most articles soften: no, not meaningfully. Lp(a) is the rare lipid number that largely ignores your lifestyle. Weight loss doesn’t reliably lower it. Exercise doesn’t lower it. Dietary studies show only small wobbles — lower-carbohydrate patterns nudging it down a few percent, very low-fat patterns sometimes nudging it slightly up — and none of these shifts approach clinical significance.

No supplement has been shown in rigorous trials to lower Lp(a) in a way that improves outcomes, whatever the label on the bottle implies. If you encounter a product marketed as an “Lp(a) fix,” treat that claim as the red flag it is; the NIH Office of Dietary Supplements is a sensible reality check before spending money.

Two truths can coexist here, and both matter:

• Your Lp(a) level is not your fault, and no amount of discipline was ever going to change it. People who blame themselves for this number are blaming themselves for their genome.
• Lifestyle still powerfully lowers your overall cardiovascular risk — the thing you actually care about. Regular activity, not smoking, healthy blood pressure, good sleep, and a Mediterranean-style eating pattern each chip away at total risk even while the Lp(a) number sits still.

Think of it this way: you can’t drain this one particular stream feeding the river, but you can drain several others. When Lp(a) is high, everything you can modify becomes more valuable, not less.

Should I take cholesterol-lowering medication if my Lp(a) is high?

This is the question behind the popular search “should I take statins if I have high lipoprotein(a),” and it deserves an unvarnished answer: the most commonly prescribed cholesterol-lowering pills do not lower Lp(a). Some studies suggest they may even nudge it up slightly, on the order of 10 percent.

So why do guidelines still often recommend them for people with high Lp(a)? Because the goal was never to fix one number — it’s to lower the total burden of harmful particles reaching your artery walls. Trial evidence shows that people who lower their LDL cholesterol reduce their risk of heart attack and stroke even when their Lp(a) stays put, and that the benefit of LDL-lowering holds in people with elevated Lp(a). In U.S. guidelines, a high Lp(a) actually functions as a “risk-enhancing factor” — a thumb on the scale that can justify starting LDL-lowering treatment earlier or pursuing lower LDL targets than your other numbers alone would suggest.

Certain injectable LDL-lowering therapies used in higher-risk patients do reduce Lp(a) modestly — typically 20 to 25 percent — though they’re prescribed for their LDL effect, and whether that Lp(a) reduction independently improves outcomes remains an open research question. For the small group with extremely high levels and progressing disease, a filtering procedure called lipoprotein apheresis, similar in spirit to dialysis, can physically remove Lp(a) from the blood.

The decision is individual, weighing your full risk picture. What the evidence does not support is skipping proven prevention because it “doesn’t touch” Lp(a). It touches the outcome, which is the point.

Can I live a long life with high lipoprotein(a)?

Yes. This bears saying clearly, because people who receive a high result often read it as a sentence rather than a statistic. Lp(a) is a risk factor — one input among many — and risk factors describe probabilities across populations, not destinies for individuals. Millions of people with elevated Lp(a) live into their eighties and nineties; many never learn they had it.

The arithmetic of risk helps here. Suppose high Lp(a) doubles a particular risk. Doubling depends entirely on the starting number: twice a 4 percent ten-year risk is 8 percent — which still means a 92 percent chance of no event over that decade. Your baseline is shaped by blood pressure, smoking status, blood sugar, kidney function, weight, activity, and age, most of which respond to effort and treatment.

That’s why preventive cardiologists describe a high Lp(a) as a reason to be meticulous, not fatalistic. In practice, that looks like the fundamentals done consistently — the same territory the American Heart Association maps out in its “Life’s Essential 8”: not smoking, regular movement, a heart-healthy eating pattern, adequate sleep, and blood pressure, cholesterol, blood sugar, and weight managed within healthy ranges.

Perspective matters too. A person who learns about their Lp(a) at 40 and acts on it may end up healthier at 70 than a neighbor with average Lp(a) who never looked under the hood. Information changed the trajectory. That is the entire argument for testing.

High Lp(a) runs in families: who else should get tested?

A high Lp(a) result is never just about you. The trait passes down in a codominant pattern, which means each first-degree relative — parent, sibling, child — has roughly a 50 percent chance of carrying a similarly elevated level. In genetics clinics this ripple-outward approach is called cascade testing, and Lp(a) is one of its cleanest use cases: one inexpensive blood test, one lifetime answer per person.

Handled well, the family conversation is a gift rather than a burden. A few suggestions from clinicians who have these talks often:

• Lead with the actionable part: “There’s a heart risk factor that runs in our family, a single blood test checks for it, and knowing changes how doctors manage everything else.”
• Skip the guilt in both directions. Nobody gave anyone this gene on purpose, and nobody earned it through bad habits.
• Adult relatives can simply request the test at their next physical; it doesn’t require a specialist.

What about children? Routine testing of kids isn’t standard practice in the U.S. Pediatric testing is generally reserved for specific contexts — a family history of familial hypercholesterolemia, very early heart disease in close relatives, or a child’s own history of stroke — and is best decided with a pediatrician. Since levels are stable, a test in early adulthood loses nothing by waiting.

Families that already share recipes and eye colors can share this too: a single data point that quietly protects the next generation.

What's coming: Lp(a)-lowering treatments in clinical trials

The most compelling reason the “why measure the untreatable” argument is collapsing: the treatable era may be arriving. Several investigational therapies designed specifically to lower Lp(a) are in large clinical trials right now. They work upstream of the particle itself, using gene-silencing techniques that tell the liver to produce far less apo(a) protein — and in early- and mid-stage studies, they have cut Lp(a) levels by roughly 80 to 95 percent with periodic injections.

Those are striking numbers, and they demand equally honest caveats. Lowering a biomarker is not the same as preventing heart attacks; medicine’s history includes therapies that moved lab values impressively without improving lives. That’s precisely what the ongoing large outcome trials are designed to settle — tens of thousands of participants with high Lp(a), followed for years, comparing real events like heart attack and stroke between treated and untreated groups. Results are expected across the mid-to-late 2020s, and until they arrive, no claim of benefit is justified. None of these therapies is approved for routine Lp(a) lowering as of this writing.

What this pipeline changes today is the logic of testing. If effective treatments emerge, the people positioned to benefit first will be those who already know their number. A once-in-a-lifetime test taken now is, among other things, a form of preparedness.

It also reframes the emotional weight of a high result: less a closed door, more a waiting room — with meaningful, proven risk reduction available in the meantime.

When to see a doctor

Two different clocks apply here, and it’s worth keeping them separate.

The emergency clock. Lp(a) itself causes no symptoms — you cannot feel a lipoprotein level. But the conditions it contributes to announce themselves urgently. Call emergency services immediately for chest pain or pressure, pain spreading to the arm, jaw, or back, sudden shortness of breath, sudden weakness or numbness on one side, trouble speaking, or sudden severe dizziness. These warrant a 911 call, not a scheduled appointment, and not a wait-and-see hour on the couch.

The routine clock. Book a regular visit to discuss Lp(a) testing if any of these describe you:

• You’ve never been tested and heart disease appeared early in your family — before 55 in men or 65 in women.
• A relative recently tested high for Lp(a).
• You’ve been told you have aortic valve stenosis, especially at a younger age.
• Your cardiovascular risk feels ambiguous and you want a fuller picture before making decisions about prevention.
• You already have a high Lp(a) result and no follow-up plan attached to it.

Come prepared. Bring whatever family history you can gather — ages at first heart attack or stroke matter more than vague recollections — and ask three specific questions: Was Lp(a) ever measured? In which units? And how does the result change my prevention plan? A ten-minute conversation built on those questions accomplishes more than a year of quiet worrying.

Frequently asked questions

Why do doctors not test for lipoprotein(a)?

Mainly historical habit: because no approved therapy specifically lowers Lp(a), many physicians followed the logic of not measuring what they couldn’t treat. Inconsistent lab units and slow-moving guidelines added friction. That’s changing — European and Canadian guidelines now recommend a once-in-a-lifetime test for all adults, U.S. guidelines treat high Lp(a) as a risk-enhancing factor, and promising therapies in trials are pushing testing into the mainstream. Often, you simply have to ask.

When should I worry about lipoprotein(a)?

A level of 125 nmol/L (about 50 mg/dL) or higher deserves a place in your prevention plan, and levels near 430 nmol/L (about 180 mg/dL) warrant a focused specialist conversation. Concern should scale with context: an elevated Lp(a) matters more alongside smoking, high blood pressure, diabetes, or early heart disease in the family. Worry itself lowers nothing — the useful response is tightening control of every risk factor you can change.

Should I take cholesterol-lowering medication if I have high lipoprotein(a)?

Possibly — but for your overall risk, not for the Lp(a) number itself. Standard cholesterol-lowering pills don’t reduce Lp(a) and may nudge it slightly higher, yet trial evidence shows lowering LDL cholesterol still cuts heart attack and stroke risk in people with high Lp(a). U.S. guidelines actually use a high Lp(a) as a reason to treat LDL earlier or more intensively. The decision is individual, so review your full risk picture with your clinician.

Can I live a long life with high lipoprotein(a)?

Yes. Lp(a) is a risk factor, not a destiny, and most people with elevated levels never have a heart attack. Even a doubled relative risk translates to a modest absolute risk when your other numbers are healthy. People who know their Lp(a) and respond by not smoking, staying active, and keeping blood pressure, blood sugar, and LDL well controlled can substantially reshape their long-term odds — often ending up healthier than peers who never checked.

Do I need to fast before an Lp(a) test?

No — fasting isn’t required for the Lp(a) measurement itself, since food doesn’t meaningfully affect the level. If your Lp(a) is drawn alongside other labs, follow the instructions given for those tests. Two practical tips: confirm the test was specifically ordered, because it isn’t part of a standard lipid panel, and ask whether your lab reports results in nmol/L, the unit many experts prefer because it counts particles rather than weighing them.

How often should the Lp(a) test be repeated?

For most adults, once in a lifetime is enough, because levels are 70 to 90 percent genetically determined and remain stable from early adulthood onward. Reasonable exceptions exist: clinicians may recheck after menopause, with significant kidney disease, with untreated thyroid problems, if the first result sat in a borderline zone, or if the test was drawn during an acute illness, which can temporarily raise levels. Otherwise, one clear result stands for decades.

What is a normal lipoprotein(a) level?

Below 75 nmol/L (roughly under 30 mg/dL) is generally considered desirable, 75 to 125 nmol/L is a borderline zone, and 125 nmol/L (about 50 mg/dL) or higher is considered elevated. Risk rises continuously rather than jumping at any single cutoff, so these thresholds are guideposts, not verdicts. Interpretation always belongs alongside your other risk factors — the same number carries different weight in different people, which is a conversation for your clinician.

Does high lipoprotein(a) cause any symptoms?

No — you cannot feel an Lp(a) level, which is exactly why testing matters. The particle works silently over decades, contributing to plaque buildup, a tendency toward clotting, and calcification of the aortic valve. Symptoms only appear when those downstream problems develop: chest pain, breathlessness, or stroke signs, all of which are emergencies requiring an immediate 911 call. The whole point of the once-in-a-lifetime test is to act during the long silent phase.

Should children be tested for lipoprotein(a)?

Not routinely in the United States. Pediatric testing is generally reserved for specific situations — a family history of familial hypercholesterolemia, very early heart disease in close relatives, or a child’s own history of stroke — and should be decided with a pediatrician. Because Lp(a) levels are genetically set and stable across life, nothing is lost by waiting until early adulthood to test, when the result can directly inform prevention decisions.

Does lipoprotein(a) affect heart valves?

Yes — this is one of Lp(a)’s most distinctive effects. The particle carries oxidized phospholipids that appear to promote calcification of the aortic valve, and studies link high Lp(a) to a two- to three-fold higher lifetime risk of calcific aortic stenosis, a progressive narrowing of the heart’s main outflow valve. If you’ve been diagnosed with aortic stenosis, particularly at a younger age than typical, an Lp(a) test is a reasonable question to raise.

References

• MedlinePlus: Lipoprotein (a) Blood Test
• NIH National Heart, Lung, and Blood Institute: Blood Cholesterol
• NHS: High Cholesterol

This article is for general information only and is not a substitute for professional medical advice. Please consult a qualified doctor about your individual situation.